Expanding the panel sounds feasible, whether it's opioids plus benzos or just opioids. Besides more drugs to possibly test for, they also hinted in the past at giving their toxicologist a full time position. When all we get are annual letters, we are left to our own devices, no pun intended, to figure out what's going on.
For example, they extol the benefits of sweat patch testing for pain management, but it sounds like it would be a much higher investment than say testing for new opioids mentioned above. Then they talk about new devices. That's dropping quite a lot on us.
Deet talked about it today. Deet talked about where the market could be heading a few months ago. It sounds like we may be entering in to riskier ventures, completely new products
They just reported almost 4 million in cash for 2017 so I think we could be around $4.7 million right now.
I estimate that the patch was a $10 million dollar investment around 1994/1995 - and I can be way off, but there are filings, still please due your DD. We do have quite some room on the balance sheet to play around with.
If they do nothing investment wise, which we know they tend to be cautious, and instead pay us the cash they have, we are at 1 times earnings. one times earnings. BUYOUT CANDIDATE AS ALWAYS.
DYODD
News 
Market Data 
Discover 
